A prospective study of total and ionized serum calcium and time to fatal prostate cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 21, Issue 10, 2012, Pages 1768-1773

  Schwartz, Gary G ^a   Skinner, Halcyon G ^b  

^a WAKE FOREST BAPTIST HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALBUMIN; CALCIUM ION;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BODY MASS; CALCIUM BLOOD LEVEL; CANCER MORTALITY; CANCER PROGNOSIS; FATALITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; VITAMIN BLOOD LEVEL;

ADULT; CALCIUM; HUMANS; MALE; MIDDLE AGED; PARATHYROID HORMONE-RELATED PROTEIN; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 84867321720     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-0585     Document Type: Article

References (41)

1. Rose DP, Boyar AP, Wynder EL. International comparisons of mortality rates for cancer of the breast, ovary, prostate, and colon, and per capita food consumption. Cancer 1986;58:2363-71. (Pubitemid 17191592)
2. Giovannucci E, Liu Y, Stampfer MJ, Willett WC. A prospective study of calcium intake and incident and fatal prostate cancer. Cancer Epidemiol Biomarkers Prev 2006;15:203-10. (Pubitemid 43342165)
3. Butler LM, Wong AS, Koh WP, Wang R, Yuan JM, Yu MC. Calcium intake increases risk of prostate cancer among Singapore Chinese. Cancer Res 2010;70:4941-8.
4. Parodi PW. Dairy product consumption and the risk of prostate cancer. Int Dairy J 2009;19:551-65.
5. Chung M, Balk EM, Brendel M, Ip S, Lau J, Lee J, et al. Vitamin D and calcium: a systematic review of health outcomes. Evid Rep Technol Assess (Full Rep) 2009;183:1-420.
6. World Cancer Research Fund/American Institute for Cancer Research. Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective. Washington DC: AICR, 2007.
7. Skinner HG, Schwartz GG. Serum calcium and incident and fatal prostate cancer in the National Health and Nutrition Examination Survey. Cancer Epidemiol Biomarkers Prev 2008;17:2302-5.
8. Skinner HG, Schwartz GG. A prospective study of total and ionized serum calcium and fatal prostate cancer. Cancer Epidemiol Biomarkers Prev 2009;18:575-8.
9. Halthur C, Johansson AL, Almquist M, Malm J, Grönberg H, Manjer J, et al. Serum calcium and the risk of prostate cancer. Cancer Causes Control. 2009;20:1205-14.
10. Lumley T. Analysis of complex survey samples. J Stat Softw 2004;9:1-19. (Pubitemid 39217809)
11. Gunter EW, Lewis BG, Koncikowski SM. Laboratory procedures used for the third National Health and Nutrition Examination Survey (NHANESIII), 1988-1994. Hyattsville (MD): Centers for Disease Control and Prevention; 1996.
12. Dickerson RN, Alexander KH, Minard G, Croce MA, Brown RO. Accuracy of methods to estimate ionized and "corrected" serum calcium concentrations in critically ill multiple trauma patients receiving specialized nutrition support. JPEN J Parenter Enteral Nutr 2004;28:133-41. (Pubitemid 38507241)
13. Hong MK, Kong J, Namdarian B, Longano A, Grummet J, Hovens CM, et al. Paraneoplastic syndromes in prostate cancer. Nat Rev Urol 2010;7:681-92.
14. Schwartz GG. The 'cocaine blues' and other problems in epidemiologic studies of vitamin D and cancer. Nutr Rev 2007;65:S75-6.
15. Etzioni R, Cha R, Feuer EJ, Davidov O. Asymptomatic incidence and duration of prostate cancer. Am J Epidemiol 1998;148:775-85. (Pubitemid 28485287)
16. Van Hemelrijck M, Hermans R, Michaelsson K, Melvin J, Garmo H, Hammar N, et al. Serum calcium and incident and fatal prostate cancer in the Swedish AMORIS study. Cancer Causes and Control 2012;23:1349-58.
17. Bryden AAG, Hoyland JA, Freemont AJ, Clarke NW, George NJR. Parathyroid hormone related peptide and receptor expression in paired primary prostate cancer and bone metastases. Br J Cancer 2002;86:322-5. (Pubitemid 34185110)
18. Clines GA. Mechanisms and treatment of hypercalcemia of malignancy. Curr Opin Endocrinol Diabetes Obes 2011;18:339-46.
19. Liao J, Li X, Koh AJ, Berry JE, Thudi N, Rosol TJ, et al. Tumor expressed PTHrP facilitates prostate cancer-induced osteoblastic lesions. Int J Cancer 2008;123:2267-78.
20. Iddon J, Bundred NJ, Hoyland J, Downey SE, Baird P, Salter D, et al. Expression of parathyroid hormone-related protein and its receptor in bone metastases from prostate cancer. J Pathol 2000;191:170-4. (Pubitemid 30394895)
21. Kristensen B, Ejlertsen B, Mouridsen HT, Loft H. Survival in breast cancer patients after the first episode of hypercalcaemia. J Intern Med 1998;244:189-98. (Pubitemid 28389655)
22. Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol 1995;13:1221-30.
23. Smith DC, Tucker JA, Trump DL. Hypercalcemia and neuroendocrine carcinoma of the prostate: a report of three cases and a review of the literature. J Clin Oncol 1992;10:499-505.
24. Murray RM, Grill V, Crinis N, Ho PW, Davison J, Pitt P. Hypocalcemic and normocalcemic hyperparathyroidism in patients with advanced prostatic cancer. J Clin Endocrinol Metab 2001;86:4133-8. (Pubitemid 32848525)
25. Nicholson S, Waxman J. Clues from hypercalcaemia. Br J Cancer 2002;86:1021-2. (Pubitemid 34438067)
26. Dai Q, Motley SS, Smith JA Jr, Concepcion R, Barocas D, Byerly S, et al. Blood magnesium, and the interaction with calcium, on the risk of high-grade prostate cancer. PLoS ONE 2011;6:e18237.
27. McMillan D, Watson W, O'Gorman P, Preston T, Scott H, McArdle C. Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer 2001;39:210-3. (Pubitemid 33694037)
28. Trautner K, Cooper EH, Haworth S, Ward AM. An evaluation of serum protein profiles in the long-term surveillance of prostatic cancer. Scand J Urol Nephrol 1980;14:143-9. (Pubitemid 11167804)
29. Richter E, Connelly RR, Moul JW. The role of pretreatment serum albumin to predict pathological stage and recurrence among radical prostatectomy cases. Prostate Cancer Prostatic Dis 2000;3:186-90.
30. Ladenson JH, Bowers GN Jr. Free calcium in serum. II. Rigor of homeostatic control, correlations with total serum calcium, and review of data on patients with disturbed calcium metabolism. Clin Chem 1973;19:575-82.
31. Reginster JY, Denis D, Bartsch V, Deroisy R, Zegels B, Franchimont P. Acute biochemical variations induced by four different calcium salts in healthy male volunteers. Osteoporos Int 1993;3:271-5. (Pubitemid 23252447)
32. Skinner HG, Schwartz GG. The relation of serum parathyroid hormone and serum calcium to serum levels of prostate-speci fi c antigen: a population-based study. Cancer Epidemiol Biomarkers Prev 2009;18:2869-73.
33. Schwartz GG. Prostate cancer, serum parathyroid hormone, and the progression of skeletal metastases. Cancer Epidemiol Biomarkers Prev 2008;17:478-83. (Pubitemid 351469195)
34. Lin KI, Chattopadhyay N, Bai M, Alvarez R, Dang CV, Baraban JM, et al. Elevated extracellular calcium can prevent apoptosis via the calcium-sensing receptor. Biochem Biophys Res Commun 1998;249:325-31. (Pubitemid 28431752)
35. Lallet-Daher H, Roudbaraki M, Bavencoffe A, Mariot P, Gackière F, Bidaux G, et al. Intermediate-conductance Ca2+-activated K+ channels (IKCa1) regulate human prostate cancer cell proliferation through a close control of calcium entry. Oncogene 2009;28:1792-806.
36. Rowland GW, Schwartz GG, John EM, Ingles SA. Calcium intake and prostate cancer among African Americans: effect modification by vitamin D receptor calcium absorption genotype. J Bone Miner Res 2012;27:187-94.
37. Yano S, Macleod RJ, Chattopadhyay N, Tfelt-Hansen J, Kifor O, Butters RR, et al. Calcium-sensing receptor activation stimulates parathyroid hormone-related protein secretion in prostate cancer cells: role of epidermal growth factor receptor transactivation. Bone 2004;35:664-72. (Pubitemid 39141867)
38. Schwartz GG. Is serum calcium a biomarker of fatal prostate cancer? Future Oncol 2009;5:577-80.
39. Ferrini R, Woolf SH. American College of Preventive Medicine practice policy. Screening for prostate cancer in American men.Am J Prev Med 1998;15:81-4. (Pubitemid 28289955)
40. Miller DC, Gruber SB, Hollenbeck BK, Montie JE, Wei JT. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst 2006;98:1134-41. (Pubitemid 44288788)
41. Botchorishvili G, Matikainen MP, Lilja H. Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer. Curr Opin Urol 2009;19:221-6.